Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer
US8337851B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 18, 2006 |
| Grant date | Dec 25, 2012 |
| Priority date | — |
| Expiry date | Mar 19, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70575
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.